Drugs / ICP-490
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06845241 | Feb 2025 → Jul 2028 expected | non-Hodgkin lymphoma | Beijing InnoCare Pharma Tech Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT05719701 | Mar 2023 → Jul 2025 | refractory plasma cell neoplasm | Beijing InnoCare Pharma Tech Co., Ltd. | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-04-17 | Beijing InnoCare Pharma Tech Co., Ltd. | Results 诺诚健华多项肿瘤管线数据在2023年美国癌症研究协会（AACR）年会上公布 innocarepharma.com ↗
在多发性骨髓瘤和非霍奇金淋巴瘤肿瘤模型中，ICP-490表现出优异的抗肿瘤活性，包括克服来那度胺的耐药性。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-04-17 | Beijing InnoCare Pharma Tech Co., Ltd. | 诺诚健华多项肿瘤管线数据在2023年美国癌症研究协会（AACR）年会上公布 innocarepharma.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ICP-490 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05719701 ↗ |